Clinical Trial Update: Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the addition of copanlisib to fulvestrant and abemaciclib for metastatic breast cancer, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Aliqopa (copanlisib)
• Faslodex (fulvestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-30